{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?houseId=1&min-answer.questionFirstMinisteriallyCorrected.=2014-10-17T09%3A05%3A37.2935139Z&answeringDeptSortName=Health&max-date=2014-10-24", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?houseId=1&min-answer.questionFirstMinisteriallyCorrected.=2014-10-17T09%3A05%3A37.2935139Z&answeringDeptSortName=Health&max-date=2014-10-24", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?houseId=1&min-answer.questionFirstMinisteriallyCorrected.=2014-10-17T09%3A05%3A37.2935139Z&answeringDeptSortName=Health&max-date=2014-10-24&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&houseId=1&min-answer.questionFirstMinisteriallyCorrected.=2014-10-17T09%3A05%3A37.2935139Z&answeringDeptSortName=Health&max-date=2014-10-24", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?houseId=1&min-answer.questionFirstMinisteriallyCorrected.=2014-10-17T09%3A05%3A37.2935139Z&answeringDeptSortName=Health&max-date=2014-10-24", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?houseId=1&min-answer.questionFirstMinisteriallyCorrected.=2014-10-17T09%3A05%3A37.2935139Z&answeringDeptSortName=Health&max-date=2014-10-24", "items" : [{"_about" : "http://data.parliament.uk/resources/100885", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100885/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100885/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:29.113Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211885"} , {"_about" : "http://data.parliament.uk/resources/100887", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100887/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100887/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Asthma"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211918"} , {"_about" : "http://data.parliament.uk/resources/100721", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100721/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100721/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Osteoporosis"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the publich purse has been spent on research into osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211732"} , {"_about" : "http://data.parliament.uk/resources/100723", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100723/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100723/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Motor Neurone Disease: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to prevent or treat symptoms of motore neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211734"} , {"_about" : "http://data.parliament.uk/resources/100728", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100728/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100728/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Motor Neurone Disease"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on research into motor neurone disease in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211730"} , {"_about" : "http://data.parliament.uk/resources/100730", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100730/answer", "answerText" : {"_value" : "

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p>

<\/p>

<\/p>

<\/p>

£ million<\/em><\/p>

<\/p>
<\/td>

2009-10<\/p><\/td>

2010-11<\/p><\/td>

2011-12<\/p><\/td>

2012-13<\/p><\/td>

2013-14<\/p><\/td><\/tr>

Asthma<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

22.2 <\/del>6.6<\/ins><\/p><\/td>

17.5 <\/del>5.3<\/ins><\/p><\/td>

17.2<\/del> 4.5<\/ins><\/p><\/td>

19.4<\/del> 3.6<\/ins><\/p><\/td>

18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.3<\/p><\/td>

1.5<\/p><\/td>

0.8<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

2.6<\/p><\/td>

3.4<\/p><\/td>

2.4<\/p><\/td>

3.4<\/p><\/td>

3.8<\/p><\/td><\/tr>

Total<\/p><\/td>

24.8<\/del> 9.2<\/ins><\/p><\/td>

21.0<\/del> 8.8<\/ins><\/p><\/td>

19.9<\/del> 7.2<\/ins><\/p><\/td>

24.3 <\/del>8.5<\/ins><\/p><\/td>

23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>

Motor Neurone Research<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

7.0<\/p><\/td>

7.5<\/p><\/td>

4.2<\/p><\/td>

4.1<\/p><\/td>

3.6<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.2<\/p><\/td>

0.2<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.1<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

0.7<\/p><\/td>

0.5<\/p><\/td><\/tr>

Total<\/p><\/td>

7.3<\/p><\/td>

7.8<\/p><\/td>

5.0<\/p><\/td>

5.5<\/p><\/td>

5.1<\/p><\/td><\/tr>

Osteoporosis<\/p><\/td><\/tr>

Medical Research Council<\/p><\/td>

6.2<\/p><\/td>

5.4<\/p><\/td>

5.1<\/p><\/td>

4.6<\/p><\/td>

5.9<\/p><\/td><\/tr>

Other Research Councils and Innovate UK<\/p><\/td>

0.0<\/p><\/td>

0.0<\/p><\/td>

0.1<\/p><\/td>

0.4<\/p><\/td>

1.0<\/p><\/td><\/tr>

National Institute for Health Research<\/p><\/td>

0.3<\/p><\/td>

0.7<\/p><\/td>

0.8<\/p><\/td>

1.3<\/p><\/td>

1.8<\/p><\/td><\/tr>

Total<\/p><\/td>

6.5<\/p><\/td>

6.1<\/p><\/td>

6.0<\/p><\/td>

6.3<\/p><\/td>

8.7<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/p>

<\/p>

The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p>

<\/p>

<\/p>

<\/p>

Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p>

<\/p>

<\/p>

<\/p>

Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100730/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-23", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Osteoporosis: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how much from the public purse has been spent on the development of new drugs to treat symptoms of osteoporosis in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"} } , "tablingMemberConstituency" : {"_value" : "Leicester West"} , "tablingMemberPrinted" : [{"_value" : "Liz Kendall"} ], "uin" : "211735"} , {"_about" : "http://data.parliament.uk/resources/100186", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/100186/answer", "answerText" : {"_value" : "

Missed or inadequate hydrocortisone administration is not currently included in the list of \u2018never events\u2019.<\/p>

<\/p>

<\/p>

<\/p>

We can confirm that the current list of Never Events is under review and there is a consultation underway which opened online on the 6 October 2014 and closes on 31 October 2014.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-10-28", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100186/answer/previousversion/24770", "answeringMember" : "http://data.parliament.uk/members/3918", "answeringMemberConstituency" : {"_value" : "Battersea"} , "answeringMemberPrinted" : {"_value" : "Jane Ellison"} } , "questionFirstAnswered" : [{"_value" : "2014-10-28T15:28:25.797Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-10-28T16:30:53.2329022Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-21", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Patients: Safety"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, whether missed or inadequate hydrocortisone administration is included in the NHS list of Never Events.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/95", "label" : {"_value" : "Biography information for Mr Andrew Smith"} } , "tablingMemberConstituency" : {"_value" : "Oxford East"} , "tablingMemberPrinted" : [{"_value" : "Mr Andrew Smith"} ], "uin" : "211233"} , {"_about" : "http://data.parliament.uk/resources/92843", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/92843/answer", "answerText" : {"_value" : "

The Health and Social Care Information Centre General and Personal Medical Services workforce census shows the number of general practitioners (GPs) by age band and gender working in the NHS in England as at 30 September each year.<\/p>

<\/p>

<\/p>

<\/p>

The attached table shows the number of GPs (excluding registrars and retainers) but including GP providers (partners) and GP others (salaried) by age band and gender as at 30 September 2013 working in the NHS in England.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"} } , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"} , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/92843/answer/attachment/1", "fileName" : {"_value" : "PQ210052 GPs by age band.xlsx"} , "title" : "GPs by Age Band Sept 2013"} , "dateOfAnswer" : {"_value" : "2014-10-20", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/92843/answer/previousversion/23112", "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"} } , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"} , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"} } , "questionFirstAnswered" : [{"_value" : "2014-10-20T16:41:38.003Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-10-20T16:54:36.8350775Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-13", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "General Practitioners"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, how many GPs working in the NHS aged (a) 25 to 35, (b) 35 to 45, (c) 45 to 55 and (d) 55 to 65 years old are (i) male and (ii) female.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/534", "label" : {"_value" : "Biography information for Chris Ruane"} } , "tablingMemberConstituency" : {"_value" : "Vale of Clwyd"} , "tablingMemberPrinted" : [{"_value" : "Chris Ruane"} ], "uin" : "210052"} , {"_about" : "http://data.parliament.uk/resources/92595", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/92595/answer", "answerText" : {"_value" : "

Effective sharing of patient information between organisations as part of a person\u2019s direct care has enormous potential to improve patient care, services and treatments and can only be done effectively if patients are given a say over how their personal information is used.<\/p>

<\/p>

<\/p>

<\/p>

The sharing of patient information, whilst protecting confidentiality, ensures the highest standards of care and clinical safety are consistently met throughout the National Health Service and where standards drop, allowing prompt action to be taken. It also helps to understand what happens to people, especially those with long term conditions, who are cared for away from hospital, and to ensure their needs are met and provides vital information needed to assist and support research into new medicines, and the better treatment of disease.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"} } , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"} , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"} , "dateOfAnswer" : {"_value" : "2014-10-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/92595/answer/previousversion/22453", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-17T08:53:07.013Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-10-17T09:05:53.0362001Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Records: Databases"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the potential benefits to the NHS of increasing the extent to which patient-level data is shared between organisations; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/204", "label" : {"_value" : "Biography information for Paul Burstow"} } , "tablingMemberConstituency" : {"_value" : "Sutton and Cheam"} , "tablingMemberPrinted" : [{"_value" : "Paul Burstow"} ], "uin" : "209873"} , {"_about" : "http://data.parliament.uk/resources/92598", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/92598/answer", "answerText" : {"_value" : "

NHS England made an announcement on the progress of the care.data project on October 7.<\/p>

<\/p>

<\/p>

<\/p>

Further details can be found at:<\/p>

<\/p>

<\/p>

<\/p>

http://www.england.nhs.uk/2014/10/07/ccgs-care-data-programme/<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3932", "label" : {"_value" : "Biography information for Dr Dan Poulter"} } , "answeringMemberConstituency" : {"_value" : "Central Suffolk and North Ipswich"} , "answeringMemberPrinted" : {"_value" : "Dr Daniel Poulter"} , "dateOfAnswer" : {"_value" : "2014-10-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/92598/answer/previousversion/22454", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} } , "questionFirstAnswered" : [{"_value" : "2014-10-17T08:57:51.97Z", "_datatype" : "dateTime"} ], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-10-17T09:05:37.2935139Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2014-10-10", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Medical Records: Databases"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what recent progress has been made on the care.data project; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/204", "label" : {"_value" : "Biography information for Paul Burstow"} } , "tablingMemberConstituency" : {"_value" : "Sutton and Cheam"} , "tablingMemberPrinted" : [{"_value" : "Paul Burstow"} ], "uin" : "209877"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&houseId=1&min-answer.questionFirstMinisteriallyCorrected.=2014-10-17T09%3A05%3A37.2935139Z&answeringDeptSortName=Health&max-date=2014-10-24", "page" : 0, "startIndex" : 1, "totalResults" : 12, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }